Palisade Bio Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company, has announced an agreement with several accredited investors to exercise existing warrants to purchase up to 4,318,905 shares of common stock. These warrants have been exercised at a reduced price of $0.9047 per share, resulting in expected gross proceeds of approximately $3.9 million. The proceeds will be used for working capital and general corporate purposes. In exchange for the immediate exercise of these warrants, investors will receive new unregistered warrants, allowing them to purchase an additional 8,637,810 shares of common stock at the same exercise price, with a term of five years. Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for this transaction.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。